Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor.

Kong EH, Heldring N, Gustafsson JA, Treuter E, Hubbard RE, Pike AC.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3593-8. Erratum in: Proc Natl Acad Sci U S A. 2006 May 23;103(21):8298.

2.

Structural insights into corepressor recognition by antagonist-bound estrogen receptors.

Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson JA, Pike AC.

J Biol Chem. 2007 Apr 6;282(14):10449-55.

3.

Small-angle X-ray scattering studies on structures of an estrogen-related receptor alpha ligand binding domain and its complexes with ligands and coactivators.

Jin KS, Park JK, Yoon J, Rho Y, Kim JH, Kim EE, Ree M.

J Phys Chem B. 2008 Aug 14;112(32):9603-12. doi: 10.1021/jp800120r.

PMID:
18646811
4.
5.

Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha.

Wärnmark A, Treuter E, Gustafsson JA, Hubbard RE, Brzozowski AM, Pike AC.

J Biol Chem. 2002 Jun 14;277(24):21862-8.

7.

Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding.

Rodriguez AL, Tamrazi A, Collins ML, Katzenellenbogen JA.

J Med Chem. 2004 Jan 29;47(3):600-11.

PMID:
14736241
8.

Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors.

Heldring N, Nilsson M, Buehrer B, Treuter E, Gustafsson JA.

Mol Cell Biol. 2004 Apr;24(8):3445-59.

9.

Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.

Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL.

Nat Struct Biol. 2002 May;9(5):359-64.

PMID:
11953755
10.

Understanding the human estrogen receptor-alpha using targeted mutagenesis.

Skafar DF, Koide S.

Mol Cell Endocrinol. 2006 Feb 26;246(1-2):83-90.

PMID:
16442702
11.

Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.

Kim JH, Lee MH, Kim BJ, Kim JH, Han SJ, Kim HY, Stallcup MR.

J Mol Endocrinol. 2005 Dec;35(3):449-64.

12.

Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity.

Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL.

J Biol Chem. 2006 Jun 30;281(26):17909-19.

13.

Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.

Kojetin DJ, Burris TP, Jensen EV, Khan SA.

Endocr Relat Cancer. 2008 Dec;15(4):851-70. doi: 10.1677/ERC-07-0281. Review.

14.
15.

A structural biologist's view of the oestrogen receptor.

Pike AC, Brzozowski AM, Hubbard RE.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):261-8. Review.

PMID:
11162934
16.
17.

Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity.

Solomon IH, Hager JM, Safi R, McDonnell DP, Redinbo MR, Ortlund EA.

J Mol Biol. 2005 Dec 16;354(5):1091-102.

PMID:
16289203
18.

Modulation of coactivator recruitment by cooperative ligand binding to human Estrogen receptor alpha and beta.

Suzuki S, Nishida S, Ohno K, Santa T.

Biol Pharm Bull. 2007 Sep;30(9):1641-7.

19.

Evolutionary identification of a subtype specific functional site in the ligand binding domain of steroid receptors.

Raviscioni M, He Q, Salicru EM, Smith CL, Lichtarge O.

Proteins. 2006 Sep 1;64(4):1046-57.

PMID:
16835908
20.

Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism.

Kallen J, Lattmann R, Beerli R, Blechschmidt A, Blommers MJ, Geiser M, Ottl J, Schlaeppi JM, Strauss A, Fournier B.

J Biol Chem. 2007 Aug 10;282(32):23231-9.

Items per page

Supplemental Content

Support Center